Google
GYRE — GYRE THERAPEUTICS INC. (Healthcare >> Biotechnology)
GYRE FAQ
What is GYRE's P/E ratio?
GYRE THERAPEUTICS INC. (GYRE) currently trades at a P/E ratio of 136.25.
What is GYRE's ROE?
GYRE THERAPEUTICS INC. reports a Return on Equity (ROE) of -6.21%.
What is GYRE's dividend yield?
GYRE THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is GYRE's Deepscope Quality Score?
Deepscope rates GYRE's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GYRE?
Deepscope's AI Timing Score for GYRE is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GYRE belong to?
GYRE THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 6.29
Price
0.10
(1.62%)
Day Change
|
|
|---|
GYRE, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
2818
|
| Magic Formula Rank by ROE |
2818
|
| Magic Formula Rank by ROIC |
2313
|
| Price | 6.29 |
| PBV / Sector |
4.03 / 4.63
|
| Earning Per Share | -0.07 |
| PE / Sector |
136.25 / 17.43
|
| PEG or PE/Growth / Sector |
-0.08 / 0.53
|
| Average 1M Daily Value |
0.60 M
GREAT
|
| Average 1W Daily Value |
0.70 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
41% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:45 |
| Symbol | GYRE |
| Name | GYRE THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 97.03 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 552.09 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 12770 High Bluff Drive, San Diego, CA, United States, 92130
Phone: 858 567 7770
Website: https://www.gyretx.com
Employees: 625
Sector: Healthcare >> Biotechnology
Description: Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
